145 related articles for article (PubMed ID: 34840226)
1. IgA Nephropathy that Developed as an Immune-related Adverse Event of Pembrolizumab Complicated with Interstitial Nephritis.
Mitarai Y; Nakashima K; Fukunaga S; Ishikawa N; Ito T; Tsubata Y; Isobe T
Intern Med; 2022 Jul; 61(13):2013-2017. PubMed ID: 34840226
[TBL] [Abstract][Full Text] [Related]
2. Renal Effects after Pembrolizumab Treatment for Non-small Cell Lung Carcinoma.
Oki R; Hirakawa Y; Kimura H; Honda K; Hinata M; Abe H; Domoto Y; Tanaka G; Nagase T; Nangaku M
Intern Med; 2020 Apr; 59(7):977-981. PubMed ID: 31813918
[TBL] [Abstract][Full Text] [Related]
3. Successful Treatment of Non-small-cell Lung Cancer with Atezolizumab Following Tubulointerstitial Nephritis Due to Pembrolizumab.
Taki T; Oda N; Fujioka Y; Mitani R; Tokura T; Takata I; Oshiro Y; Takigawa N
Intern Med; 2020 Jul; 59(13):1639-1642. PubMed ID: 32269191
[TBL] [Abstract][Full Text] [Related]
4. Interstitial nephritis with pembrolizumab: A case report and review.
Peláez Bejarano A; Montero Pérez O; Inoriza Rueda A; Garrido Martínez MT
J Oncol Pharm Pract; 2021 Jun; 27(4):1046-1051. PubMed ID: 33040674
[TBL] [Abstract][Full Text] [Related]
5. Anti-glomerular basement membrane glomerulonephritis concurrent with membranous nephropathy and acute tubular interstitial nephritis in a lung cancer patient treated with pembrolizumab.
Hoshina A; Endo S
CEN Case Rep; 2023 May; 12(2):230-236. PubMed ID: 36401746
[TBL] [Abstract][Full Text] [Related]
6. IgA nephropathy after pembrolizumab therapy for mesothelioma.
Wang R; Das T; Takou A
BMJ Case Rep; 2020 Nov; 13(11):. PubMed ID: 33257374
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological characteristics of kidney injury in non-small cell lung cancer patients under combination therapy including pembrolizumab.
Aratani S; Sugano T; Shimizu A; Seike M; Kashiwagi T; Gemma A; Sakai Y
CEN Case Rep; 2022 Feb; 11(1):97-104. PubMed ID: 34406602
[TBL] [Abstract][Full Text] [Related]
8. Dabigatran-related Nephropathy Complicated by Tubulointerstitial Nephritis in a Patient with a Normal Renal Function and Undiagnosed IgA Nephropathy.
Iwafuchi Y; Ito Y; Imai N; Oyama Y; Narita I
Intern Med; 2024 Jun; 63(11):1615-1621. PubMed ID: 37866913
[TBL] [Abstract][Full Text] [Related]
9. Dramatic, significant metabolic response to a one-time pembrolizumab treatment following a relapse of pre-existing organizing pneumonia in a patient with advanced non-small cell lung cancer: A case report.
Kato M; Mori M; Miura K; Asao T; Motomura H; Nishino K; Ko R; Koyama R; Hayashi T; Takahashi K
Thorac Cancer; 2021 Nov; 12(22):3076-3079. PubMed ID: 34617405
[TBL] [Abstract][Full Text] [Related]
10. Delayed immune-related neutropenia with hepatitis by pembrolizumab.
Nakako S; Nakashima Y; Okamura H; Tani Y; Ueda T; Makuuchi Y; Kuno M; Takakuwa T; Nishimoto M; Koh H; Nakamae H; Hino M
Immunotherapy; 2022 Feb; 14(2):101-105. PubMed ID: 34758635
[TBL] [Abstract][Full Text] [Related]
11. IgA Nephropathy after Nivolumab Therapy for Postoperative Recurrence of Lung Squamous Cell Carcinoma.
Kishi S; Minato M; Saijo A; Murakami N; Tamaki M; Matsuura M; Murakami T; Nagai K; Abe H; Nishioka Y; Doi T
Intern Med; 2018 May; 57(9):1259-1263. PubMed ID: 29279511
[TBL] [Abstract][Full Text] [Related]
12. Cilostazol-induced acute tubulointerstitial nephritis accompanied by IgA nephropathy: a case report.
Shima H; Tashiro M; Yamada S; Matsuura M; Okada K; Doi T; Minakuchi J; Kawashima S
BMC Nephrol; 2018 Mar; 19(1):52. PubMed ID: 29506491
[TBL] [Abstract][Full Text] [Related]
13. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR
J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704
[TBL] [Abstract][Full Text] [Related]
14. Tubulointerstitial nephritis and IgA nephropathy in a patient with advanced lung cancer treated with long-term gefitinib.
Masutani K; Fujisaki K; Maeda H; Toyonaga J; Inoshima I; Takayama K; Katafuchi R; Hirakata H; Tsuruya K; Iida M
Clin Exp Nephrol; 2008 Oct; 12(5):398-402. PubMed ID: 18575950
[TBL] [Abstract][Full Text] [Related]
15. Tubulointerstitial nephritis and uveitis syndrome complicated by IgA nephropathy and Graves' disease: a case report.
Shimamura Y; Tsushima T; Moniwa N; Hasegawa K; Ogawa Y; Takizawa H
J Med Case Rep; 2014 Sep; 8():305. PubMed ID: 25216854
[TBL] [Abstract][Full Text] [Related]
16. Successful Steroid Treatment of Pembrolizumab-induced Agranulocytosis That Developed after Splenectomy in a Patient with Non-small-cell Lung Cancer.
Okuzumi S; Kamata H; Emoto K; Shimizu T; Otake S; Irie H; Chubachi S; Ikemura S; Yasuda H; Fukunaga K
Intern Med; 2023 Jul; 62(14):2113-2121. PubMed ID: 36450461
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab-induced hypothyroidism caused reversible increased serum creatinine levels: a case report.
Matsuoka N; Tsuji K; Ichihara E; Hara T; Fukushima K; Toma K; Kitamura S; Inagaki K; Sugiyama H; Wada J
BMC Nephrol; 2020 Mar; 21(1):113. PubMed ID: 32234009
[TBL] [Abstract][Full Text] [Related]
18. Acute Tubulointerstitial Nephritis: A Case Report on Rare Adverse Effect of Pembrolizumab.
Basnet S; Dhital R; Tharu B
Medicina (Kaunas); 2019 May; 55(5):. PubMed ID: 31117208
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab-induced severe oral mucositis in a patient with squamous cell carcinoma of the lung: A case study.
Yoon SY; Han JJ; Baek SK; Kim HJ; Maeng CH
Lung Cancer; 2020 Sep; 147():21-25. PubMed ID: 32652370
[TBL] [Abstract][Full Text] [Related]
20. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer.
Komiya K; Nakamura T; Abe T; Ogusu S; Nakashima C; Takahashi K; Kimura S; Sueoka-Aragane N
Thorac Cancer; 2019 Sep; 10(9):1798-1804. PubMed ID: 31328416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]